Modified reoviral therapy

Details Modified reoviral therapy Modified reoviral therapy

2007-04-27

2010-10-05

Lucas, Zachariah (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S009411, C424S093100

Reexamination Certificate

active

07807179

ABSTRACT:
The present invention relates to hyperproliferative diseases. Specifically, the present invention encompasses pharmaceutical compositions comprising a modified Reoviridae virus, wherein the Reoviridae virus is conjugated to a hydroxylated hydrocarbon or a polycationic polymer to reduce the clearance of the composition and reduce the immunogenicity of the composition. Yet further, the invention relates to methods of treating a hyperproliferative disease by administering to a patient an effective amount of the modified Reoviridae virus.

REFERENCES:
patent: 5192540 (1993-03-01), Kuo et al.
patent: 5658779 (1997-08-01), Krupey et al.
patent: 6110461 (2000-08-01), Lee et al.
patent: 6136307 (2000-10-01), Lee et al.
patent: 6455038 (2002-09-01), Lee et al.
patent: 6569426 (2003-05-01), Smith et al.
patent: WO-00/50051 (2000-08-01), None
patent: WO-00/50051 (2000-12-01), None
Smith, Edward R., et al.; Oncolytic viruses as novel anticancer agents: turning one scourge against another; Exp. Opin. Invest. Drugs (2000) 9(2):311-327.
Norman, Kara L., et al.; Reovirus as a novel oncolytic agent; The Journal of Clinical Investigation, vol. 105 (8), pp. 1035-1038; Apr. 2000.
Wodarz, Dominik; Viruses as Antitumor Weapons: Defining Conditions for Tumor Remission; Cancer Research 61, pp. 3501-3507, Apr. 15, 2001.
Coffey, Matthew, et al.; Reovirus Therapy of Tumors with Activated Ras Pathway; Science, vol. 282, pp. 1332-1334, Nov. 13, 1998.
Ogris, M., et al.; PEGylated DNA/transferrin-PE1 complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery; Gene Therapy (1999) 6, 595-605.
Croyle, Maria A., et al.; Technical Report—Development of a Rapid Method for the PEGylation of Adenoviruses with Enhanced Transduction and Improved Stability under Harsh Storage Conditions; Human Gene Therapy 11:1713-1722 (Aug. 10, 2000).
O'Riordan, Catherine R., et al.; PEGylation of Adenovirus with Retention of Infectivity and Protection from Neutralizing Antibody in Vitro and in Vivo; Human Gene Therapy 10:1349-1358 (May 20, 1999).
Wen, Xiaoxia, et al.; Poly(ethylene glycol)-Conjugated Anti-EGF Receptor Antibody C225 with Radiometal Chelator Attached to the Termini of Polymer Chains; Bioconjugate Chem. 12:545-553, 2001.
Yang, Xiao-Dong, et al.; Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy; Critical Reviews in Oncology Hematology 38:17-23, 2001.
Ruoslahti, Erkki; Fibronectin and Its Integrin Receptors in Cancer; Advances in Cancer Research 76:1-20, 1999.
Robbins, J., et al. “Haemophilus Influenzae Type b Infections”, Bacterial Vaccines (1984) pp. 289-316.
March, S., et al., “A Simplified Method for Cyanogen Bromide Activation of Agarose for Affinity Chromatograph”, Analytical Biochem., vol. 60 (1974) pp. 149-152.
Bethell, G., et al., “A Novel Method of Activation of Cross-Linked Agaroses with 1,1′ —Carbonyldiimidazole Which Gives a Matrix for Affinity Chromatography Devoid of Additional Charged Group,” The Jol. of Bio. Chem., vol. 254, No. 8, (Apr. 1979) pp. 2572-2574.
Tarrand, J., et. al., “Clonal Characterization of the Human IgG Antibody Repertoire to Haemophilius Infulenzae Type B Polysaccharide”, The Jol. of Immun., vol. 7, vol. 143, (Apr. 1989), pp. 2519-2526.
Tomasulo, S., et al., “Trittation of Endotoxin”, Biochemica Biophysica Actg. vol. 400 (1975) pp. 399-406.
Bobbitt, J., et al., “Periodate Oxidation of Carbohydrates”, Dept. of Chemistry, The Ohio State University, Ohio pp. 1-41.
Anderson, P. et al., “Vaccines Consisting of Periodate-Cleaved Oligosaccharides from the Capsule of Haemophilus Influenzae Type b coupled to a Protein Carrier: Structural and Temporal Requirements for Priming in the Human Infant”, Jol. of Immun. (Aug. 1986) vol. 137, No. 4., pp. 1181-1186.
Haahti, Eero, et al., “The uropygiols: identification of the unsaponifiable constituent of a diester wax from chicken preen glands”, Jol. of Lipids Res., (1987) vol. 8, pp. 131-137.
Axen, R., et al., “Chemical Coupling of Peptides and Proteins to Polysaccharides by Means of Cyanogen Halides”, Nature, vol. 214 (Jun. 1987), pp. 1302-1304.
Bobbitt, J., et al., “Periodate Oxidation of Carbohydrates”, Dept. of Chemistry, The Ohio State University, Ohio pp. 1-41, 1956.

Affiliated with

Also associated with

Rating

Modified reoviral therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modified reoviral therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified reoviral therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4219411